Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to -$140.0 million.

  • Arcutis Biotherapeutics' Net Income towards Common Stockholders rose 117.84% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 77.33%. This contributed to the annual value of -$140.0 million for FY2024, which is 46.58% up from last year.
  • According to the latest figures from FY2024, Arcutis Biotherapeutics' Net Income towards Common Stockholders is -$140.0 million, which was up 46.58% from -$262.1 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Net Income towards Common Stockholders high stood at -$136.6 million for FY2020, and its period low was -$311.5 million during FY2022.
  • Its 3-year average for Net Income towards Common Stockholders is -$237.9 million, with a median of -$262.1 million in 2023.
  • In the last 5 years, Arcutis Biotherapeutics' Net Income towards Common Stockholders plummeted by 51.02% in 2021 and then spiked by 46.58% in 2024.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' Net Income towards Common Stockholders stood at -$136.6 million in 2020, then tumbled by 51.02% to -$206.4 million in 2021, then crashed by 50.93% to -$311.5 million in 2022, then increased by 15.83% to -$262.1 million in 2023, then spiked by 46.58% to -$140.0 million in 2024.